Murine and human data have indicated that tumors and tumor-bearing hosts may exhibit nearly normal or markedly altered circadian rhythms. Amplitude damping, phase shifts, and/or period (t) change, including appearance of ultradian rhythms (with t F 20 hr) usually become more prominent at late stages of cancer development. The extent of rhythm alterations also varies according to tumor type, growth rate and level of differentiation. While ''group chronotherapy,'' i.e., administration of the same chronomodulated schedule to cancer patients, has increased chemotherapy efficacy and/or tolerability, cancer patients' individual circadian rhythms now need to be explored on a large scale, in order to estimate the incidence of cancer-associated circadian-system alterations and to understand the underlying mechanisms. Correlations between such alterations and patient outcome must be established in order to specify the need for individualized chronomodulated delivery schedules and/or specific rhythmoriented therapy, especially in patients with circadian-system disturbances. Int. J. Cancer, 70:241-247, 1997.r 1997 Wiley-Liss, Inc.Biological functions are modulated by rhythms along several periodic time-scales, i.e., ultradian (with a period, t, shorter than 20 hr), circadian (t approx. 24 hr) or infradian (t . 28 hr). Circadian rhythms are endogenous, genetically based, and coordinated by at least one biological clock, the supra-chiasmatic nucleus (SCN). The circadian periodicity of the SCN can be calibrated by environmental cycles with a t approaching 24 hr. The 24-hr light-dark cycle plays such a role, via specific neuronal pathways and neuromediators, and via darkness-induced secretion of melatonin.